Not Yet Recruiting PHASE3 INTERVENTIONAL 2-arm NCT07400107

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight (AMAZE 8)

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 8)

Sponsor: Novo Nordisk A/S

Conditions Diabetes Mellitus, Type 2 Obesity Overweight

Interventions NNC0487-0111 Placebo (matched to NNC0487-0111) Placebo (matched to semaglutide) Semaglutide

Updated 2 times since 2026 Last updated: Mar 11, 2026 Started: May 20, 2026 Primary completion: Dec 12, 2028 Completion: Jan 26, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Diabetes Mellitus, Type 2 and Obesity, this trial is actively recruiting participants. The trial is conducted by Novo Nordisk A/S and has accumulated 2 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

2 versions recorded

Mar 2026 — Present [monthly]

Not Yet Recruiting PHASE3
Feb 2026 — Mar 2026 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adana /yüreği̇r, Turkey (Türkiye) , Alcabideche, Portugal , Aligarh, India , Almada, Portugal , Ankara, Turkey (Türkiye) , Bacau, Romania , Bad Oeynhausen, Germany , Bangalore, India , Bangkok, Thailand , Battalgazi / Malatya, Turkey (Türkiye) and 92 more locations